1. Introduction {#sec1}
===============

Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with a prevalence of 1 in 3500 people. This fully penetrant condition is characterized by multiple café au lait spots, axillary and inguinal freckling, cutaneous neurofibromas, and iris Lisch nodules \[[@B1], [@B2]\]. Less common manifestations include plexiform neurofibromas, optic nerve, and other central nervous system gliomas, scoliosis, tibial dysplasia, and vasculopathy. Additionally, patients with NF1 have increased relative risk of developing malignant peripheral nerve sheath tumors, leukemia, rhabdomyosarcoma, gastrointestinal stromal tumors, phaeochromocytoma, and breast cancer \[[@B3]--[@B8]\].

Metaplastic breast carcinoma (MBC) is uncommon, accounting for less than 5% of breast carcinoma \[[@B9]\]. This tumor consists of a heterogeneous group of malignancies which may correspond to mixed epithelial and sarcomatoid components, as well as primary squamous cell carcinoma, or mixed adenocarcinoma and squamous cell carcinoma \[[@B10]\]. Interestingly, there is only one case of MBC affecting a NF1 patient previously reported in the English literature \[[@B11]\].

The present study presents a rare case of a patient with NF1 who developed MBC, which metastasized to oral cavity. In addition, the importance of investigating breast tumors in NF1 patients is emphasized.

2. Case Report {#sec2}
==============

A 53-year-old woman was referred to the Stomatology Department, complaining of teeth mobility and a swelling in her mouth with 10 days of evolution. During the anamnesis, the patient denied any alcohol consumption and related that she had smoked for 18 years and quit 4 years ago. Her medical history included NF1 and left mastectomy 20 days previously due to metaplastic carcinoma.

On physical examination, the patient had multiple café au lait macules and cutaneous neurofibromas located on cervical, dorsal, abdominal, and upper members (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}). The intraoral examination revealed a large mass with necrotic surface in the left retromolar area, measuring approximately 5 centimeters, which caused important trismus ([Figure 1(c)](#fig1){ref-type="fig"}). The main diagnostic hypothesis was metastasis of MBC. In addition, under local anesthesia, the patient underwent incisional biopsy.

The histopathological analysis of the oral cavity lesion revealed a malignant neoplasia with spindle cell pattern and areas with osteoclast-like cells (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}) suggestive of metastasis of MBC. Subsequently, the specimens of mastectomy were reviewed. The epithelial component of breast tumor exhibited areas of*in situ* ([Figure 2(c)](#fig2){ref-type="fig"}) and invasive ductal carcinoma ([Figure 2(d)](#fig2){ref-type="fig"}) and also areas with squamous differentiation. However, the major part of the tumor was composed of a sarcomatoid component with areas of hemangiopericytic pattern ([Figure 2(e)](#fig2){ref-type="fig"}) and others with osteoclast-like cells ([Figure 2(f)](#fig2){ref-type="fig"}).

On immunohistochemical analysis, the breast tumor cells ([Table 1](#tab1){ref-type="table"}) were negative for estrogen and progesterone receptors and c-Erb-B2 was only positive in carcinoma*in situ* area. Vimentin was positive in the sarcomatous component, while cytokeratin AE1/AE3 and p63 were seen in few cells of the same component. Furthermore, S-100 and smooth muscle actin were positive in focal areas and CD68 was positive in osteoclast-like areas. A strong nuclear positivity was found against p53 and Ki-67 antibodies ([Figure 3](#fig3){ref-type="fig"}). The immunohistochemical analysis of the mandibular biopsy specimen ([Table 1](#tab1){ref-type="table"}) showed similar findings to those of the breast tumor, except for total negativity of p63 and S-100. Considering the clinical, histopathological, and immunohistochemical features, the diagnosis of oral metastasis of the sarcomatous component of MBC was confirmed.

The patient was referred to the Department of Clinical Oncology for evaluation. Computed tomography showed multiple lung and liver nodules and osteolytic lesion on the second costal arch. Moreover, all lesions were strongly suggestive of metastases. Chemotherapy with doxorubicin and ifosfamide was started but was interrupted due to pancytopenia. There was progression of the disease and the patient died 75 days after the diagnosis of oral metastasis.

3. Discussion {#sec3}
=============

NF1 has been associated with cancer predisposition. The most common tumors are gliomas, malignant peripheral nerve sheath tumors, leukemia, and rhabdomyosarcoma \[[@B3], [@B12]\]. Although Brasfield and Das Gupta \[[@B13]\] reported in the 70s that 5 out of 54 women with NF1 developed breast carcinoma, only recently this association was recognized. Considering that breast cancer is already a common tumor in women, it would be difficult to know whether the coexistence of NF1 and breast cancer is a coincidence or a real predisposition. Sharif et al. \[[@B5]\] evaluated 304 women with NF1 and 14 had breast cancer (11 with infiltrating ductal carcinoma and 3 with infiltrating lobular carcinoma). Interestingly, these women had an early age of onset of breast cancer, with a median age of diagnosis of 44 years. Recently, Madanikia et al. \[[@B6]\] reviewed charts of 124 women with NF1 who were 20 years old or older and found 4 cases of breast cancer. Wang et al. \[[@B7]\] found 11 cases of breast cancer among a cohort of 76 women with NF1. Seminog and Goldacre \[[@B8]\] also showed a high risk of breast cancer, especially a threefold risk in women under 50. All these studies agree that women with NF1 are at higher risk for breast cancer than the general population, particularly when they are younger than 50 years old. Furthermore, these patients may have a delay in diagnosis since breast tumors may be misdiagnosed as NF1 manifestations \[[@B15], [@B14], [@B16]\]. In the present case, a 53-year-old woman with NF1 presented with a very aggressive breast cancer which metastasized to mandible, ribs, lung, and liver. Interestingly, on anamnesis, the patient related that she had undergone a mastectomy 20 days before, but she was being investigated due to breast nodule for 7 months.

We reviewed the English language literature and found 63 patients with NF1 who developed breast malignant tumors. Furthermore, most cases were ductal invasive carcinoma and less commonly lobular carcinoma ([Table 2](#tab2){ref-type="table"}) \[[@B5]--[@B7], [@B11]--[@B31]\]. Interestingly, we found one well-documented case of MBC (carcinosarcoma) \[[@B11]\]. In the present case, the patient presented with metaplastic carcinoma with very scarce epithelial component, with the major part of the tumor composed of a sarcomatoid component. The oral lesion was exclusively formed by sarcomatoid fraction.

Metaplastic carcinoma is a very rare type of breast cancer, which accounts for less than 5% of breast carcinomas \[[@B9]\]. It is a poorly differentiated tumor characterized by coexistence of adenocarcinoma with areas of matrix producing, spindle-cell, sarcomatous, and/or squamous differentiation. The present case showed wide undifferentiated spindle cell elements; areas of hemangiopericytic pattern and abundant osteoclast-like cells were also observed. In contrast, the epithelial component was the minor part formed by invasive ductal carcinoma and carcinoma*in situ*. In addition, overexpression of c-Erb-B2 in metaplastic carcinoma is rare (4%), while estrogen and progesterone receptors are frequently negative. Consequently, this tumor is usually referred to as "triple negative" \[[@B32], [@B33]\]. Similar to most cases previously reported in the literature, the present case exhibited a triple-negative immunoprofile and also had a high histological grade, which caused many anomalous immunoexpressions, such as focal positivity to SMA, S-100 antibodies, and coexpression of vimentin and CK AE1/AE3 (1% of the cells) in the sarcomatous component. In addition, p53 and Ki-67 markers showed high proliferative rate in both breast and mandible tumors ([Table 1](#tab1){ref-type="table"}; Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Metastatic lesions comprise 1% of all oral cavity malignancies and usually represent the evidence of wide spread disease. According to the review of Hirshberg et al. \[[@B34]\] the most common primary sites for oral metastases in women are breast, female genital organs, kidney, and colorectum, while in men they are lung, kidney, liver, and prostate. Still, this review showed that the mandibular bone is more frequently affected than the oral soft tissues in a proportion of 2 : 1, with the mandible being the most common location and the molar area the most frequently involved. In our case, we believe that the oral metastasis occurred in the gingiva, since there was rapid growth of the necrotic lesion and absence of specific symptoms such as pain and paresthesia. In addition, computerized tomography showed only a tumor mass emerging from the mandible without significant bone involvement. Other clinical findings of our patient included lung, bone, and liver metastases, which are the main sites of metastatic MBC \[[@B35]\]. Similar to our case, McMillan and Edwards \[[@B17]\] reported a case of bilateral mandibular metastases of breast carcinoma in a 41-year-old woman with NF1. It is noteworthy that the patient was only 27 years of age when she underwent a right radical mastectomy for removal of a breast carcinoma. Differently from our case, the oral lesion presented as a lump on the right jaw with an intact mucosa covering and the authors believed that the initial site of localization was within the bone.

Despite the follow-up of patients with NF1 and breast cancer, the literature data are not clear. Brasfield and Das Gupta \[[@B13]\] observed that all 5 patients died within 5 years of the diagnosis of breast cancer. This fact led them to question whether neurofibromatosis could influence the prognosis of patients with cancer. Nevertheless, some authors correlated the poor prognosis with late diagnosis since breast tumors may be misdiagnosed as NF1 manifestations as commented before \[[@B15], [@B14], [@B16]\]. Considering the 64 patients, information about follow-up was found in 36 patients. Of these, 17 are alive, 16 dead of breast cancer, and 3 dead due to other causes ([Table 2](#tab2){ref-type="table"}).

In summary, since breast cancer has been associated in the literature with NF1, affected patients require screening for breast tumors. Thereby, early identification of breast cancer is important for appropriate management and better prognosis of the disease. Interestingly, the case presented here is the second reported in the English language literature referring to an MBC involving a woman with NF1, along with the curious finding that there was metastasis of the sarcomatous component to oral cavity.
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![(a) Abdominal surface presenting café au lait macules and multiple cutaneous neurofibromas. (b) Upper member with cutaneous neurofibromas. (c) Intraoral view showing an extensive tumor with necrotic surface located on the left retromolar area.](CRIONM2014-719061.001){#fig1}

![(a) Histological findings of malignant neoplasia of the oral cavity, showing atypical spindle cells with a storiform arrangement (H&E stain, ×40). (b) Areas with osteoclast-like cells (H&E stain, ×400). (c) Histological findings of metaplastic breast carcinoma with carcinoma*in situ* area beside the sarcomatous component (H&E, ×100). (d) Invasive ductal carcinoma (H&E, ×40). (e) Sarcomatoid pattern with hemangiopericytic area (H&E, ×40). (f) Sarcomatoid component with osteoclast-like cells (H&E, ×200).](CRIONM2014-719061.002){#fig2}

![Immunoreactivity of metaplastic carcinoma. (a) Strong immunoreactivity for vimentin in the sarcomatous component. (b) Immunoreactivity for cytokeratin AE1/AE3 is present in few cells of the sarcomatous component. (c) Reactivity for smooth muscle actin in focal area. (d) Immunoreactivity for CD68 in osteoclast-like cells. (e) Nuclear immunoreactivity for Ki-67. (f) Expression of p53 (polymer-HRP detection system, biotin-free).](CRIONM2014-719061.003){#fig3}

###### 

Immunohistochemical features observed in both carcinoma and sarcomatoid components and in both breast and mandibular tumors.

  Antibody                   Clone                               Breast Cancer             Oral metastasis            
  -------------------------- ----------------------------------- ------------------------- -------------------------- --------------------------
  ER                         SP1---DAKO                          −                         −                          −
                                                                                                                      
  PR                         PgR636---DAKO                       −                         −                          −
                                                                                                                      
  C-erbB-e                   Polyclonal---DAKO                   (1+) invasive carcinoma   −                          −
  (3+) carcinoma *in situ*   \(0\)                               \(0\)                                                
                                                                                                                      
  CK5                        XM26 (mouse)---Neomarkers           −                         −                          −
                                                                                                                      
  CK14                       LL002 (mouse)---Thermo Scientific   \+ carcinoma *in situ*    −                          −
                                                                                                                      
  CKAE1/AE3                  AE1-AE3---DAKO                      \+                        \+                         \+
  1% neoplastic cells        1% neoplastic cells                                                                      
                                                                                                                      
  p63                        4A4---DAKO                          −                         \+                         −
  10% neoplastic cells                                                                                                
                                                                                                                      
  p53                        D0-7---DAKO                         \+                        \+                         \+
  20% neoplastic cells       40% neoplastic cells                80% neoplastic cells                                 
                                                                                                                      
  Ki-67                      MIB-1---DAKO                        Proliferative activity    Proliferative activity     Proliferative activity
  50%                        80%                                 90%                                                  
                                                                                                                      
  Vimentin                   V9---DAKO                           −                         \+                         \+
                                                                                                                      
  SMA                        1A4---DAKO                          −                         \+ focal areas             \+ focal areas
                                                                                                                      
  Desmin                     D33---DAKO                          −                         −                          −
                                                                                                                      
  Myogenin                   F5D---DAKO                          −                         −                          −
                                                                                                                      
  Myo-D1                     5.8A---DAKO                         −                         −                          −
                                                                                                                      
  S-100                      Polyclonal---DAKO                   −                         \+ focal areas             −
                                                                                                                      
  CD68                       KP1---DAKO                          −                         \+ osteoclast-like cells   \+ osteoclast-like cells

ER: estrogen receptor; PR: progesterone receptor; CK: cytokeratin; SMA: smooth muscle actin.

###### 

Total of patients with NF1 who developed breast carcinoma considering only English language literature.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Authors                              *N*      Breast cancer subtype            Age (years)                             Follow-up (months)
  ------------------------------------ -------- -------------------------------- --------------------------------------- ----------------------
  Brasfield and Das Gupta \[[@B13]\]   5        Breast carcinoma\*               1 patient 39, the others not informed   All dead within 60

                                                                                                                         

  McMillan and Edwards \[[@B17]\]      1        Spheroidal-cell carcinoma        27                                      Dead, 168

                                                                                                                         

  El-Zawahry et al. \[[@B18]\]         2        Lobular carcinoma\               40\                                     Not informed
                                                Breast carcinoma\*               70                                      

                                                                                                                         

  Zöller et al. \[[@B19]\]             2        Ductal carcinoma\                38\                                     Dead 36\
                                                Ductal carcinoma                 66                                      Dead 24

                                                                                                                         

  Nakamura et al. \[[@B15]\]           1        Scirrhous carcinoma              49                                      Dead 5

                                                                                                                         

  Murayama et al. \[[@B14]\]           1        Ductal carcinoma                 66                                      Alive 8

                                                                                                                         

  Ceccaroni et al. \[[@B20]\]          2        Breast carcinoma\* \             52\                                     Not informed
                                                Breast carcinoma\*               66                                      

                                                                                                                         

  Satgé et al. \[[@B21]\]              1        Ductal carcinoma                 23                                      Alive 168

                                                                                                                         

  Güran and Safali \[[@B12]\]          2        Ductal carcinoma\                23\                                     Not informed
                                                Ductal carcinoma                 58                                      

                                                                                                                         

  Posada and Chakmakjian \[[@B22]\]    1        Lobular carcinoma                74                                      Alive 36

                                                                                                                         

  Walker et al. \[[@B23]\]             5        4 ductal carcinoma\              Mean age 46.4                           Not informed
                                                1 lobular carcinoma                                                      

                                                                                                                         

  Natsiopoulos et al. \[[@B11]\]       1        Metaplastic carcinoma            60                                      Alive 30

                                                                                                                         

  Sharif et al. \[[@B5]\]              14       11 ductal carcinoma\             Mean age 43.5                           5 died mean 66\
                                                3 lobular carcinoma                                                      3 died other causes\
                                                                                                                         6 alive mean 54

                                                                                                                         

  Hasson et al. \[[@B24]\]             1        Ductal carcinoma                 49                                      Not informed

                                                                                                                         

  Invernizzi et al. \[[@B25]\]         1        Ductal carcinoma                 60                                      Alive 36

                                                                                                                         

  Alamsamimi et al. \[[@B26]\]         1        Ductal carcinoma                 51                                      Alive 24

                                                                                                                         

  Hegyi et al. \[[@B27]\]              1        Malignant myoepithelioma         41                                      Not informed

                                                                                                                         

  Salemis et al. \[[@B16]\]            1        Ductal carcinoma                 59                                      Alive 20

                                                                                                                         

  Bhargava et al. \[[@B28]\]           1        Ductal carcinoma                 58                                      Alive 13

                                                                                                                         

  Takeuchi et al. \[[@B29]\]           1        Ductal and lobular carcinoma     69                                      Alive 6

                                                                                                                         

  Zhou et al. \[[@B30]\]               1        Ductal carcinoma                 48                                      Alive 8

                                                                                                                         

  Madanikia et al. \[[@B6]\]           4        3 ductal carcinoma\              Not informed                            Not informed
                                                1 unknown                                                                

                                                                                                                         

  Wang et al. \[[@B7]\]                11       10 ductal carcinoma\             Mean age 48.8                           Not informed
                                                1 lobular and ductal carcinoma                                           

                                                                                                                         

  Campos et al. \[[@B31]\]             2        Breast carcinoma\* \             40\                                     Dead\
                                                Ductal carcinoma                 35                                      Alive 24

                                                                                                                         

  Present case                         1        Metaplastic carcinoma            53                                      Dead 3

                                                                                                                         

  Total                                **64**                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------

\*Subtype not informed.
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